|
1.
|
Burbelo PD, Lebovitz EE, Bren KE, Bayat A, Paviol S, Wenzlau JM, Barriga KJ, Rewers M, Harlan DM, Iadarola MJ. Extrapancreatic autoantibody profiles in type I diabetes. PLoS One. 2012; 7(9):e45216.
|
|
|
|
|
2.
|
Feigenbaum K, Brooks PG, Chamberlain CE, Cochran E, Adams-McLean A, Malek R, Harlan DM. The Clinical Center's Blood Glucose Management Service: A Story in Quality Integrated Care. Diabetes Educ. 2012 Mar; 38(2):194-206.
|
|
|
|
|
3.
|
Greiner DL, Brehm MA, Hosur V, Harlan DM, Powers AC, Shultz LD. Humanized mice for the study of type 1 and type 2 diabetes. Ann N Y Acad Sci. 2011 Dec; 1245(1):55-8.
|
|
|
|
|
4.
|
Soleimanpour SA, Hirshberg B, Bunnell DJ, Sumner AE, Ader M, Remaley AT, Rother KI, Rickels MR, Harlan DM. Metabolic function of a suboptimal transplanted islet mass in nonhuman primates on rapamycin monotherapy. Cell Transplant. 2012; 21(6):1297-304.
|
|
|
|
|
5.
|
Brown RJ, Wijewickrama RC, Harlan DM, Rother KI. Uncoupling intensive insulin therapy from weight gain and hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2011 Apr; 13(4):457-60.
|
|
|
|
|
6.
|
Rother KI, Harlan DM. Comment on: Keenan et al. (2010) Residual Insulin Production and Pancreatic {beta}-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853. Diabetes. 2010 Dec; 59(12):e26.
|
|
|
|
|
7.
|
Harlan DM, Lee MM. Infant formula, autoimmune triggers, and type 1 diabetes. N Engl J Med. 2010 Nov 11; 363(20):1961-3.
|
|
|
|
|
8.
|
Perl S, Kushner JA, Buchholz BA, Meeker AK, Stein GM, Hsieh M, Kirby M, Pechhold S, Liu EH, Harlan DM, Tisdale JF. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab. 2010 Oct; 95(10):E234-9.
|
|
|
|
|
9.
|
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul; 33(7):1674-85.
|
|
|
|
|
10.
|
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010 Jul-Aug; 60(4):207-21.
|
|
|
|
|
11.
|
Pechhold S, Stouffer M, Walker G, Martel R, Seligmann B, Hang Y, Stein R, Harlan DM, Pechhold K. Transcriptional analysis of intracytoplasmically stained, FACS-purified cells by high-throughput, quantitative nuclease protection. Nat Biotechnol. 2009 Nov; 27(11):1038-42.
|
|
|
|
|
12.
|
Rother KI, Spain LM, Wesley RA, Digon BJ, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009 Dec; 32(12):2251-7.
|
|
|
|
|
13.
|
Harlan DM, Kenyon NS, Korsgren O, Roep BO. Current advances and travails in islet transplantation. Diabetes. 2009 Oct; 58(10):2175-84.
|
|
|
|
|
14.
|
Khan MH, Harlan DM. Counterpoint: clinical islet transplantation: not ready for prime time. Diabetes Care. 2009 Aug; 32(8):1570-4.
|
|
|
|
|
15.
|
Rother KI, Brown RJ, Morales MM, Wright E, Duan Z, Campbell C, Hardin DS, Popovic J, McEvoy RC, Harlan DM, Orlander PR, Brod SA. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care. 2009 Jul; 32(7):1250-5.
|
|
|
|
|
16.
|
Craig AT, Gavrilova O, Dwyer NK, Jou W, Pack S, Liu E, Pechhold K, Schmidt M, McAlister VJ, Chiorini JA, Blanchette-Mackie EJ, Harlan DM, Owens RA. Transduction of rat pancreatic islets with pseudotyped adeno-associated virus vectors. Virol J. 2009; 6:61.
|
|
|
|
|
17.
|
Liu EH, Digon BJ, Hirshberg B, Chang R, Wood BJ, Neeman Z, Kam A, Wesley RA, Polly SM, Hofmann RM, Rother KI, Harlan DM. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia. 2009 Jul; 52(7):1369-80.
|
|
|
|
|
18.
|
Shen HC, Adem A, Ylaya K, Wilson A, He M, Lorang D, Hewitt SM, Pechhold K, Harlan DM, Lubensky IA, Schmidt LS, Linehan WM, Libutti SK. Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS One. 2009; 4(4):e4897.
|
|
|
|
|
19.
|
Pechhold K, Koczwara K, Zhu X, Harrison VS, Walker G, Lee J, Harlan DM. Blood glucose levels regulate pancreatic beta-cell proliferation during experimentally-induced and spontaneous autoimmune diabetes in mice. PLoS One. 2009; 4(3):e4827.
|
|
|
|
|
20.
|
Lin HM, Lee JH, Yadav H, Kamaraju AK, Liu E, Zhigang D, Vieira A, Kim SJ, Collins H, Matschinsky F, Harlan DM, Roberts AB, Rane SG. Transforming growth factor-beta/Smad3 signaling regulates insulin gene transcription and pancreatic islet beta-cell function. J Biol Chem. 2009 May 1; 284(18):12246-57.
|
|
|
|
|
21.
|
Pechhold K, Zhu X, Harrison VS, Lee J, Chakrabarty S, Koczwara K, Gavrilova O, Harlan DM. Dynamic changes in pancreatic endocrine cell abundance, distribution, and function in antigen-induced and spontaneous autoimmune diabetes. Diabetes. 2009 May; 58(5):1175-84.
|
|
|
|
|
22.
|
Pechhold K, Chakrabarty S, Harlan DM. Cytotoxic T cell-mediated diabetes in RIP-CD80 transgenic mice: autoantigen peptide sensitivity and fine specificity. Ann N Y Acad Sci. 2007 Apr; 1103:132-42.
|
|
|
|
|
23.
|
Perl S, Hirshberg B, Harlan DM, Tisdale JF. How much insulin is enough? A quantitative assessment of the transdifferentiaton potential of liver. Diabetologia. 2007 Mar; 50(3):690-2.
|
|
|
|
|
24.
|
Ren J, Jin P, Wang E, Liu E, Harlan DM, Li X, Stroncek DF. Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation. J Transl Med. 2007; 5:1.
|
|
|
|
|
25.
|
Liu EH, Siegel RM, Harlan DM, O'Shea JJ. T cell-directed therapies: lessons learned and future prospects. Nat Immunol. 2007 Jan; 8(1):25-30.
|
|
|
|
|
26.
|
Taylor-Fishwick DA, Bowman A, Hamblet N, Bernard P, Harlan DM, Vinik AI. Islet neogenesis associated protein transgenic mice are resistant to hyperglycemia induced by streptozotocin. J Endocrinol. 2006 Sep; 190(3):729-37.
|
|
|
|
|
27.
|
Neeman Z, Hirshberg B, Harlan D, Wood BJ. Radiologic aspects of islet cell transplantation. Curr Diab Rep. 2006 Aug; 6(4):310-5.
|
|
|
|
|
28.
|
Dy EC, Harlan DM, Rother KI. Assessment of islet function following islet and pancreas transplantation. Curr Diab Rep. 2006 Aug; 6(4):316-22.
|
|
|
|
|
29.
|
Bagenstose LM, Agarwal RK, Silver PB, Harlan DM, Hoffmann SC, Kampen RL, Chan CC, Caspi RR. Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance. J Immunol. 2005 Jul 1; 175(1):124-30.
|
|
|
|
|
30.
|
Harlan DM, von Herrath M. Immune intervention with anti-CD3 in diabetes. Nat Med. 2005 Jul; 11(7):716-8.
|
|
|
|
|
31.
|
Kang EM, Zickler PP, Burns S, Langemeijer SM, Brenner S, Phang OA, Patterson N, Harlan D, Tisdale JF. Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol. 2005 Jun; 33(6):699-705.
|
|
|
|
|
32.
|
Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun; 54(6):1763-9.
|
|
|
|
|
33.
|
Brissova M, Fowler MJ, Nicholson WE, Chu A, Hirshberg B, Harlan DM, Powers AC. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem. 2005 Sep; 53(9):1087-97.
|
|
|
|
|
34.
|
Fowler M, Virostko J, Chen Z, Poffenberger G, Radhika A, Brissova M, Shiota M, Nicholson WE, Shi Y, Hirshberg B, Harlan DM, Jansen ED, Powers AC. Assessment of pancreatic islet mass after islet transplantation using in vivo bioluminescence imaging. Transplantation. 2005 Apr 15; 79(7):768-76.
|
|
|
|
|
35.
|
Liu EH, Rother KI, Harlan DM. Islet transplantation and the challenges of treating type 1 diabetes. Discov Med. 2005 Feb; 5(25):43-9.
|
|
|
|
|
36.
|
Naftanel MA, Harlan DM. Pancreatic islet transplantation. PLoS Med. 2004 Dec; 1(3):e58; quiz e75.
|
|
|
|
|
37.
|
Minn AH, Lan H, Rabaglia ME, Harlan DM, Peculis BA, Attie AD, Shalev A. Increased insulin translation from an insulin splice-variant overexpressed in diabetes, obesity, and insulin resistance. Mol Endocrinol. 2005 Mar; 19(3):794-803.
|
|
|
|
|
38.
|
Neeman Z, Hirshberg B, Tal MG, Wood BJ, Harlan DM. Pulmonary angiography for the diagnosis of thromboembolic events in the non-human primate. Transplantation. 2004 Oct 15; 78(7):1025-9.
|
|
|
|
|
39.
|
Ferrant JL, Benjamin CD, Cutler AH, Kalled SL, Hsu YM, Garber EA, Hess DM, Shapiro RI, Kenyon NS, Harlan DM, Kirk AD, Burkly LC, Taylor FR. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int Immunol. 2004 Nov; 16(11):1583-94.
|
|
|
|
|
40.
|
Rother KI, Harlan DM. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest. 2004 Oct; 114(7):877-83.
|
|
|
|
|
41.
|
Harlan DM, Rother KI. Islet transplantation as a treatment for diabetes. N Engl J Med. 2004 May 13; 350(20):2104; author reply 2104.
|
|
|
|
|
42.
|
Shalev A, Patterson NB, Hirshberg B, Rother KI, Harlan DM. Resistin serum levels in type 1 diabetes pre- and post-islet transplantation. Metabolism. 2004 Apr; 53(4):403-4.
|
|
|
|
|
43.
|
Harlan DM. Gene-altered islets for transplant: giant leap or small step? Endocrinology. 2004 Feb; 145(2):463-6.
|
|
|
|
|
44.
|
Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. Insulin secretion in type 1 diabetes. Diabetes. 2004 Feb; 53(2):426-33.
|
|
|
|
|
45.
|
Minn AH, Kayton M, Lorang D, Hoffmann SC, Harlan DM, Libutti SK, Shalev A. Insulinomas and expression of an insulin splice variant. Lancet. 2004 Jan 31; 363(9406):363-7.
|
|
|
|
|
46.
|
Tal MG, Hirshberg B, Neeman Z, Bunnell D, Soleimanpour S, Bacher J, Patterson N, Chang R, Harlan DM. Induction of diabetes in nonhuman primates by means of temporary arterial embolization and selective arterial injection of streptozotocin. Radiology. 2004 Jan; 230(1):163-8.
|
|
|
|
|
47.
|
Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA. 2003 Dec 3; 290(21):2817-23.
|
|
|
|
|
48.
|
Kayton ML, Costouros NG, Lorang D, Alexander HR, Hewitt SM, Cochran C, Shalev A, Harlan D, Skarulis MC, Gorden P, Libutti SK. Peak stimulated insulin secretion is associated with specific changes in gene expression profiles in sporadic insulinomas. Surgery. 2003 Dec; 134(6):982-7; discussion 987-8.
|
|
|
|
|
49.
|
Hirshberg B, Rother KI, Digon III BJ, Venstrom J, Harlan DM. State of the art: islet transplantation for the cure of type 1 diabetes mellitus. Rev Endocr Metab Disord. 2003 Dec; 4(4):381-9.
|
|
|
|
|
50.
|
Hirshberg B, Rother KI, Digon BJ, Lee J, Gaglia JL, Hines K, Read EJ, Chang R, Wood BJ, Harlan DM. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care. 2003 Dec; 26(12):3288-95.
|
|
|
|
|
51.
|
Xu H, Elster EA, Blair PJ, Burkly LC, Tadaki DK, Harlan DM, Kirk AD. Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. Am J Transplant. 2003 Nov; 3(11):1350-4.
|
|
|
|
|
52.
|
Digon BJ, Rother KI, Hirshberg B, Harlan DM. Sirolimus-induced interstitial pneumonitis in an islet transplant recipient. Diabetes Care. 2003 Nov; 26(11):3191.
|
|
|
|
|
53.
|
Minn AH, Patterson NB, Pack S, Hoffmann SC, Gavrilova O, Vinson C, Harlan DM, Shalev A. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun. 2003 Oct 17; 310(2):641-5.
|
|
|
|
|
54.
|
Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003 Dec; 144(12):5149-58.
|
|
|
|
|
55.
|
Hirshberg B, Preston EH, Xu H, Tal MG, Neeman Z, Bunnell D, Soleimanpour S, Hale DA, Kirk AD, Harlan DM. Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model. Transplantation. 2003 Jul 15; 76(1):55-60.
|
|
|
|
|
56.
|
Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation. 2003 Jul 15; 76(1):120-9.
|
|
|
|
|
57.
|
Tadaki DK, Williams A, Lee KP, Kirk AD, Harlan DM. Porcine CD80: cloning, characterization, and evidence for its role in direct human T-cell activation. Xenotransplantation. 2003 May; 10(3):252-8.
|
|
|
|
|
58.
|
Hirshberg B, Rother KI, Harlan DM. Islet transplantation: where do we stand now? Diabetes Metab Res Rev. 2003 May-Jun; 19(3):175-8; discussion 175.
|
|
|
|
|
59.
|
Xu H, Montgomery SP, Preston EH, Tadaki DK, Hale DA, Harlan DM, Kirk AD. Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. J Immunol. 2003 Mar 1; 170(5):2776-82.
|
|
|
|
|
60.
|
Pechhold K, Karges W, Blum C, Boehm BO, Harlan DM. Beta cell-specific CD80 (B7-1) expression disrupts tissue protection from autoantigen-specific CTL-mediated diabetes. J Autoimmun. 2003 Feb; 20(1):1-13.
|
|
|
|
|
61.
|
Hirshberg B, Mog S, Patterson N, Leconte J, Harlan DM. Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using edmonton protocol immunosuppression. J Clin Endocrinol Metab. 2002 Dec; 87(12):5424-9.
|
|
|
|
|
62.
|
Montgomery SP, Xu H, Tadaki DK, Celniker A, Burkly LC, Berning JD, Cruzata F, Elster EA, Gray G, Kampen RL, Swanson SJ, Harlan DM, Kirk AD. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation. 2002 Nov 27; 74(10):1365-9.
|
|
|
|
|
63.
|
Swanson SJ, Hale DA, Mannon RB, Kleiner DE, Cendales LC, Chamberlain CE, Polly SM, Harlan DM, Kirk AD. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet. 2002 Nov 23; 360(9346):1662-4.
|
|
|
|
|
64.
|
Xu H, Tadaki DK, Elster EA, Burkly LC, Berning JD, Cruzata F, Kampen RL, Montgomery SP, Patterson NB, Harlan DM, Kirk AD. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation. 2002 Oct 15; 74(7):940-3.
|
|
|
|
|
65.
|
Shalev A, Pise-Masison CA, Radonovich M, Hoffmann SC, Hirshberg B, Brady JN, Harlan DM. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology. 2002 Sep; 143(9):3695-8.
|
|
|
|
|
66.
|
Chute JP, Saini AA, Chute DJ, Wells MR, Clark WB, Harlan DM, Park J, Stull MK, Civin C, Davis TA. Ex vivo culture with human brain endothelial cells increases the SCID-repopulating capacity of adult human bone marrow. Blood. 2002 Dec 15; 100(13):4433-9.
|
|
|
|
|
67.
|
Hoffmann SC, Stanley EM, Cox ED, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant. 2002 Jul; 2(6):560-7.
|
|
|
|
|
68.
|
Hirshberg B, Montgomery S, Wysoki MG, Xu H, Tadaki D, Lee J, Hines K, Gaglia J, Patterson N, Leconte J, Hale D, Chang R, Kirk AD, Harlan DM. Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site. Diabetes. 2002 Jul; 51(7):2135-40.
|
|
|
|
|
69.
|
Shalev A, Blair PJ, Hoffmann SC, Hirshberg B, Peculis BA, Harlan DM. A proinsulin gene splice variant with increased translation efficiency is expressed in human pancreatic islets. Endocrinology. 2002 Jul; 143(7):2541-7.
|
|
|
|
|
70.
|
Harlan DM, Karp CL, Matzinger P, Munn DH, Ransohoff RM, Metzger DW. Immunological concerns with bioengineering approaches. Ann N Y Acad Sci. 2002 Jun; 961:323-30.
|
|
|
|
|
71.
|
Harlan DM. Islet cell allotransplantation as a model system for a bioengineering approach to reparative medicine: immunological concerns. Ann N Y Acad Sci. 2002 Jun; 961:331-4.
|
|
|
|
|
72.
|
Harlan DM, Metzger DW, Karp CL, Matzinger P, Munn DH, Ransohoff RM. Immune response to engineered tissues and cells: breakout session summary. Ann N Y Acad Sci. 2002 Jun; 961:350-1.
|
|
|
|
|
73.
|
Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30; 346(22):1692-8.
|
|
|
|
|
74.
|
Montgomery SP, Mog SR, Xu H, Tadaki DK, Hirshberg B, Berning JD, Leconte J, Harlan DM, Hale D, Kirk AD. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant. 2002 Apr; 2(4):381-5.
|
|
|
|
|
75.
|
Chute JP, Clark W, Saini A, Wells M, Harlan D. Rescue of hematopoietic stem cells following high-dose radiation injury using ex vivo culture on endothelial monolayers. Mil Med. 2002 Feb; 167(2 Suppl):74-7.
|
|
|
|
|
76.
|
Xu H, Arnaud F, Tadaki DK, Burkly LC, Harlan DM, Kirk AD. Human platelets activate porcine endothelial cells through a CD154-dependent pathway. Transplantation. 2001 Dec 15; 72(11):1858-61.
|
|
|
|
|
77.
|
Elster EA, Xu H, Tadaki DK, Montgomery S, Burkly LC, Berning JD, Baumgartner RE, Cruzata F, Marx R, Harlan DM, Kirk AD. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation. 2001 Nov 15; 72(9):1473-8.
|
|
|
|
|
78.
|
Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation. 2001 Oct 27; 72(8):1444-50.
|
|
|
|
|
79.
|
Montgomery SP, Hale DA, Hirshberg B, Harlan DM, Kirk AD. Preclinical evaluation of tolerance induction protocols and islet transplantation in non-human primates. Immunol Rev. 2001 Oct; 183:214-22.
|
|
|
|
|
80.
|
Cox ED, Hoffmann SC, DiMercurio BS, Wesley RA, Harlan DM, Kirk AD, Blair PJ. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation. 2001 Aug 27; 72(4):720-6.
|
|
|
|
|
81.
|
Kirk AD, Tadaki DK, Celniker A, Batty DS, Berning JD, Colonna JO, Cruzata F, Elster EA, Gray GS, Kampen RL, Patterson NB, Szklut P, Swanson J, Xu H, Harlan DM. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation. 2001 Aug 15; 72(3):377-84.
|
|
|
|
|
82.
|
Kirk AD, Blair PJ, Tadaki DK, Xu H, Harlan DM. The role of CD154 in organ transplant rejection and acceptance. Philos Trans R Soc Lond B Biol Sci. 2001 May 29; 356(1409):691-702.
|
|
|
|
|
83.
|
Pechhold K, Patterson NB, Blum C, Fleischacker CL, Boehm BO, Harlan DM. Low dose streptozotocin-induced diabetes in rat insulin promoter-mCD80-transgenic mice is T cell autoantigen-specific and CD28 dependent. J Immunol. 2001 Feb 15; 166(4):2531-9.
|
|
|
|
|
84.
|
Xu H, Elster E, Batty D, Berning J, Burkly L, Kampen R, Swanson S, Tadaki D, Harlan D, Kirk A. Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. Transplant Proc. 2001 Feb-Mar; 33(1-2):223-4.
|
|
|
|
|
85.
|
Elster EA, Xu H, Tadaki DK, Burkly LC, Berning JD, Baumgartner RE, Cruzata F, Patterson NB, Harlan DM, Kirk AD. Primate skin allotransplantation with anti-CD154 monotherapy. Transplant Proc. 2001 Feb-Mar; 33(1-2):675-6.
|
|
|
|
|
86.
|
Gaglia JL, Harlan DM. Transplantation tolerance. Curr Dir Autoimmun. 2001; 4:283-307.
|
|
|
|
|
87.
|
Chute JP, Saini A, Wells M, Clark W, Wu A, St Louis D, Blair P, Harlan D, Kaushal S. Preincubation with endothelial cell monolayers increases gene transfer efficiency into human bone marrow CD34(+)CD38(-) progenitor cells. Hum Gene Ther. 2000 Dec 10; 11(18):2515-28.
|
|
|
|
|
88.
|
Tadaki DK, Craighead N, Saini A, Celniker A, Burkly LC, Lee KP, Chute JP, Harlan DM, Kirk AD. Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. Transplantation. 2000 Jul 15; 70(1):162-7.
|
|
|
|
|
89.
|
Blair PJ, Riley JL, Harlan DM, Abe R, Tadaki DK, Hoffmann SC, White L, Francomano T, Perfetto SJ, Kirk AD, June CH. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med. 2000 Feb 21; 191(4):651-60.
|
|
|
|
|
90.
|
Herrera PL, Harlan DM, Vassalli P. A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways: possible role of membrane TNF. Proc Natl Acad Sci U S A. 2000 Jan 4; 97(1):279-84.
|
|
|
|
|
91.
|
Harlan DM, Kirk AD. The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? JAMA. 1999 Sep 15; 282(11):1076-82.
|
|
|
|
|
92.
|
Kenyon NS, Chatzipetrou M, Masetti M, Ranuncoli A, Oliveira M, Wagner JL, Kirk AD, Harlan DM, Burkly LC, Ricordi C. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A. 1999 Jul 6; 96(14):8132-7.
|
|
|
|
|
93.
|
Saha B, Saini A, Germond R, Perrin PJ, Harlan DM, Davis TA. Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF. Eur J Immunol. 1999 Jul; 29(7):2319-29.
|
|
|
|
|
94.
|
Kenyon NS, Fernandez LA, Lehmann R, Masetti M, Ranuncoli A, Chatzipetrou M, Iaria G, Han D, Wagner JL, Ruiz P, Berho M, Inverardi L, Alejandro R, Mintz DH, Kirk AD, Harlan DM, Burkly LC, Ricordi C. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes. 1999 Jul; 48(7):1473-81.
|
|
|
|
|
95.
|
Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999 Jun; 5(6):686-93.
|
|
|
|
|
96.
|
Knechtle SJ, Kirk AD, Fechner JH, Hong X, Dong Y, Hamawy MM, Harlan DM. Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. Transplant Proc. 1999 May; 31(3B Suppl):27S-28S.
|
|
|
|
|
97.
|
St Louis DC, Woodcock JB, Franzoso G, Blair PJ, Carlson LM, Murillo M, Wells MR, Williams AJ, Smoot DS, Kaushal S, Grimes JL, Harlan DM, Chute JP, June CH, Siebenlist U, Lee KP, Fransozo G. Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model. J Immunol. 1999 Mar 15; 162(6):3237-48.
|
|
|
|
|
98.
|
Saha B, Chattopadhyay S, Germond R, Harlan DM, Perrin PJ. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection. Eur J Immunol. 1998 Dec; 28(12):4213-20.
|
|
|
|
|
99.
|
Sobel DO, Goyal D, Ahvazi B, Yoon JW, Chung YH, Bagg A, Harlan DM. Low dose poly I:C prevents diabetes in the diabetes prone BB rat. J Autoimmun. 1998 Aug; 11(4):343-52.
|
|
|
|
|
100.
|
Davis TA, Saini AA, Blair PJ, Levine BL, Craighead N, Harlan DM, June CH, Lee KP. Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. J Immunol. 1998 Apr 15; 160(8):3689-97.
|
|
|
|
|
101.
|
Horspool JH, Perrin PJ, Woodcock JB, Cox JH, King CL, June CH, Harlan DM, St Louis DC, Lee KP. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J Immunol. 1998 Mar 15; 160(6):2706-14.
|
|
|
|
|
102.
|
Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A. 1997 Aug 5; 94(16):8789-94.
|
|
|
|
|
103.
|
Pechhold K, Patterson NB, Craighead N, Lee KP, June CH, Harlan DM. Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. J Immunol. 1997 May 15; 158(10):4921-9.
|
|
|
|
|
104.
|
Blair PJ, Riley JL, Carroll RG, St Louis DC, Levine BL, Saha B, Lee KP, Perrin PJ, Harlan DM, June CH. CD28 co-receptor signal transduction in T-cell activation. Biochem Soc Trans. 1997 May; 25(2):651-7.
|
|
|
|
|
105.
|
Saha B, Jaklic B, Harlan DM, Gray GS, June CH, Abe R. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J Immunol. 1996 Nov 1; 157(9):3869-75.
|
|
|
|
|
106.
|
Saha B, Harlan DM, Lee KP, June CH, Abe R. Protection against lethal toxic shock by targeted disruption of the CD28 gene. J Exp Med. 1996 Jun 1; 183(6):2675-80.
|
|
|
|
|
107.
|
Imagawa A, Hanafusa T, Itoh N, Miyagawa J, Nakajima H, Namba M, Kuwajima M, Tamura S, Kawata S, Matsuzawa Y, Harlan DM. Islet-infiltrating t lymphocytes in insulin-dependent diabetic patients express CD80 (B7-1) and CD86 (B7-2). J Autoimmun. 1996 Jun; 9(3):391-6.
|
|
|
|
|
108.
|
Harlan DM, Barnett MA, Abe R, Pechhold K, Patterson NB, Gray GS, June CH. Very-low-dose streptozotocin induces diabetes in insulin promoter-mB7-1 transgenic mice. Diabetes. 1995 Jul; 44(7):816-23.
|
|
|
|
|
109.
|
Harlan DM, Abe R, Lee KP, June CH. Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion. Clin Immunol Immunopathol. 1995 May; 75(2):99-111.
|
|
|
|
|
110.
|
Herrera PL, Harlan DM, Fossati L, Izui S, Huarte J, Orci L, Vassalli JD, Vassalli P. A CD8+ T-lymphocyte-mediated and CD4+ T-lymphocyte-independent autoimmune diabetes of early onset in transgenic mice. Diabetologia. 1994 Dec; 37(12):1277-9.
|
|
|
|
|
111.
|
Harlan DM, Hengartner H, Huang ML, Kang YH, Abe R, Moreadith RW, Pircher H, Gray GS, Ohashi PS, Freeman GJ, et al. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc Natl Acad Sci U S A. 1994 Apr 12; 91(8):3137-41.
|
|
|
|
|
112.
|
Harlan DM, Graff JM, Stumpo DJ, Eddy RL, Shows TB, Boyle JM, Blackshear PJ. The human myristoylated alanine-rich C kinase substrate (MARCKS) gene (MACS). Analysis of its gene product, promoter, and chromosomal localization. J Biol Chem. 1991 Aug 5; 266(22):14399-405.
|
|
|
|
